{
    "hands_on_practices": [
        {
            "introduction": "The action of any drug begins with its binding to a molecular target. For a dipeptidyl peptidase-4 (DPP-4) inhibitor like sitagliptin, this crucial first step is occupying the active site of the DPP-4 enzyme. This practice grounds this abstract concept in quantitative terms by having you derive the relationship between inhibitor concentration and fractional enzyme occupancy, a key measure of target engagement that forms the basis of understanding dose-response curves .",
            "id": "4958112",
            "problem": "Dipeptidyl peptidase-4 (DPP-4) is a serine protease that cleaves incretin hormones such as glucagon-like peptide-1 (GLP-1). Small-molecule inhibitors like sitagliptin bind reversibly to the DPP-4 active site and compete with substrate for binding, which is the defining feature of competitive, reversible inhibition: the inhibitor binds to the same site as the substrate through noncovalent interactions that are at equilibrium and dissociable. In a substrate-free in vitro system at equilibrium, consider the enzyme-inhibitor binding scheme\n$$\nE + I \\rightleftharpoons EI,\n$$\nwith the equilibrium dissociation constant defined by the law of mass action as\n$$\nK_{i} \\equiv \\frac{[E][I]}{[EI]}.\n$$\nLet the total enzyme concentration be conserved as\n$$\n[E]_{\\text{tot}} = [E] + [EI].\n$$\nStarting only from these definitions, derive an expression for the fractional occupancy of DPP-4 by inhibitor,\n$$\nf \\equiv \\frac{[EI]}{[E]_{\\text{tot}}},\n$$\nin terms of $[I]$ and $K_i$, and then evaluate $f$ numerically for sitagliptin with $K_i = 18 \\ \\text{nM}$ at a free inhibitor concentration of $[I] = 72 \\ \\text{nM}$. Express the final result as a unitless decimal fraction and round your answer to $3$ significant figures.",
            "solution": "The problem statement is analyzed and found to be valid. It is scientifically grounded in the principles of enzyme kinetics and chemical equilibrium, is well-posed with sufficient and consistent information, and is expressed objectively. No flaws corresponding to the invalidity criteria are present.\n\nThe primary objective is to derive an expression for the fractional occupancy of the enzyme DPP-4 by an inhibitor, denoted as $f$, and then to calculate its numerical value for given concentrations.\n\nThe fractional occupancy, $f$, is defined as the ratio of the concentration of the enzyme-inhibitor complex, $[EI]$, to the total enzyme concentration, $[E]_{\\text{tot}}$:\n$$\nf \\equiv \\frac{[EI]}{[E]_{\\text{tot}}}\n$$\nThe total enzyme concentration is conserved, meaning it is the sum of the free enzyme concentration, $[E]$, and the concentration of the enzyme-inhibitor complex, $[EI]$:\n$$\n[E]_{\\text{tot}} = [E] + [EI]\n$$\nSubstituting this conservation equation into the definition of $f$ yields:\n$$\nf = \\frac{[EI]}{[E] + [EI]}\n$$\nTo express $f$ in terms of the free inhibitor concentration, $[I]$, and the equilibrium dissociation constant, $K_i$, we must eliminate $[E]$ from the equation. The equilibrium dissociation constant for the reaction $E + I \\rightleftharpoons EI$ is given by the law of mass action:\n$$\nK_{i} \\equiv \\frac{[E][I]}{[EI]}\n$$\nThis equation can be rearranged to express the free enzyme concentration, $[E]$, in terms of other species:\n$$\n[E] = K_i \\frac{[EI]}{[I]}\n$$\nNow, we substitute this expression for $[E]$ back into our equation for $f$:\n$$\nf = \\frac{[EI]}{K_i \\frac{[EI]}{[I]} + [EI]}\n$$\nThe term $[EI]$ is common to the numerator and both terms in the denominator's sum. It can be factored out from the denominator:\n$$\nf = \\frac{[EI]}{[EI] \\left( \\frac{K_i}{[I]} + 1 \\right)}\n$$\nCanceling the $[EI]$ term from the numerator and denominator gives:\n$$\nf = \\frac{1}{\\frac{K_i}{[I]} + 1}\n$$\nTo simplify this expression into a more conventional form, we can multiply the numerator and the denominator by $[I]$:\n$$\nf = \\frac{1 \\cdot [I]}{\\left( \\frac{K_i}{[I]} + 1 \\right) \\cdot [I]} = \\frac{[I]}{K_i + [I]}\n$$\nThis is the final derived expression for the fractional occupancy, $f$, in terms of $[I]$ and $K_i$.\n\nNext, we evaluate $f$ numerically using the provided values for sitagliptin: $K_i = 18 \\ \\text{nM}$ and $[I] = 72 \\ \\text{nM}$.\nSubstituting these values into the derived formula:\n$$\nf = \\frac{72 \\ \\text{nM}}{18 \\ \\text{nM} + 72 \\ \\text{nM}}\n$$\nThe concentration units (nM) in the numerator and denominator cancel, yielding a dimensionless fraction as expected.\n$$\nf = \\frac{72}{90} = \\frac{8 \\times 9}{10 \\times 9} = \\frac{8}{10} = 0.8\n$$\nThe problem requires the final result to be rounded to $3$ significant figures. Therefore, the value $0.8$ is expressed as $0.800$.",
            "answer": "$$\n\\boxed{0.800}\n$$"
        },
        {
            "introduction": "Once an inhibitor binds to its target, what is the functional consequence? Building directly upon the principle of target occupancy, this exercise explores how a competitive DPP-4 inhibitor alters the enzyme's catalytic efficiency. You will derive how the inhibitor's presence increases the apparent Michaelis constant ($K_m$) and then calculate the resulting decrease in GLP-1 degradation velocity, bridging the gap between molecular binding and its impact on enzyme kinetics .",
            "id": "4958195",
            "problem": "A Glucagon-Like Peptide-1 (GLP-1) molecule is degraded by the enzyme Dipeptidyl Peptidase-4 (DPP-4). Consider the standard Michaelis–Menten scheme for enzyme catalysis, where the enzyme $E$ binds substrate $S$ to form an enzyme–substrate complex $ES$, which then turns over to product with rate constant $k_{\\mathrm{cat}}$. The inhibitor $I$ binds reversibly and competitively to the free enzyme $E$ at the same binding site as $S$, forming the inactive complex $EI$. Let the equilibrium dissociation constant for inhibitor binding be $K_i$, defined by the relation $K_i = \\frac{[E][I]}{[EI]}$ at equilibrium. Assume the steady-state approximation for $[ES]$, conservation of total enzyme $[E]_{\\mathrm{T}}$, and that inhibitor binding does not change $k_{\\mathrm{cat}}$ for the $ES$ complex.\n\nStarting from these fundamental definitions and assumptions, derive the apparent Michaelis constant in the presence of competitive inhibitor for DPP-4 acting on GLP-1, and use it to predict the change in degradation velocity at a fixed substrate concentration. Then compute the ratio of the initial velocity in the presence of inhibitor to the initial velocity in the absence of inhibitor at the same substrate concentration. Use the following experimentally measured parameters for DPP-4 acting on GLP-1:\n- $K_m = 3.0\\,\\mu\\mathrm{M}$,\n- $V_{\\max} = 120\\,\\mathrm{pmol}\\,\\mathrm{min}^{-1}\\,\\mathrm{mg}^{-1}$,\n- $[S] = 1.50\\,\\mu\\mathrm{M}$,\n- $[I] = 0.90\\,\\mu\\mathrm{M}$,\n- $K_i = 0.60\\,\\mu\\mathrm{M}$.\n\nRound your final ratio to four significant figures. Express your answer as a pure number without units.",
            "solution": "The problem requires the derivation of the effect of a competitive inhibitor on enzyme kinetics, specifically for DPP-4 acting on GLP-1, and the calculation of a resulting velocity ratio. The problem is scientifically sound and well-posed.\n\nThe enzymatic reaction follows the Michaelis-Menten model. The substrate ($S$) binds to the free enzyme ($E$) to form an enzyme-substrate complex ($ES$), which then yields the product ($P$) and regenerates the free enzyme.\n$$E + S \\underset{k_{-1}}{\\stackrel{k_1}{\\rightleftharpoons}} ES \\stackrel{k_{\\mathrm{cat}}}{\\longrightarrow} E + P$$\nThe competitive inhibitor ($I$) binds reversibly to the free enzyme at the same active site as the substrate, forming an inactive enzyme-inhibitor complex ($EI$).\n$$E + I \\underset{k_{-i}}{\\stackrel{k_i}{\\rightleftharpoons}} EI$$\nThe initial velocity of the reaction, $v$, is the rate of product formation, which is proportional to the concentration of the enzyme-substrate complex:\n$$v = k_{\\mathrm{cat}} [ES]$$\nThe total enzyme concentration, $[E]_{\\mathrm{T}}$, is conserved and is the sum of the concentrations of free enzyme, enzyme-substrate complex, and enzyme-inhibitor complex.\n$$[E]_{\\mathrm{T}} = [E] + [ES] + [EI]$$\nThe dissociation constant for the inhibitor, $K_i$, is defined by the equilibrium relationship:\n$$K_i = \\frac{[E][I]}{[EI]}$$\nFrom this, we can express the concentration of the enzyme-inhibitor complex in terms of the free enzyme concentration:\n$$[EI] = \\frac{[E][I]}{K_i}$$\nSubstituting this into the enzyme conservation equation gives:\n$$[E]_{\\mathrm{T}} = [E] + [ES] + \\frac{[E][I]}{K_i} = [E] \\left(1 + \\frac{[I]}{K_i}\\right) + [ES]$$\nThis allows us to express the free enzyme concentration, $[E]$, in terms of the total enzyme concentration, $[E]_{\\mathrm{T}}$, and the enzyme-substrate complex concentration, $[ES]$:\n$$[E] = \\frac{[E]_{\\mathrm{T}} - [ES]}{1 + \\frac{[I]}{K_i}}$$\nThe steady-state assumption posits that the concentration of the $ES$ complex is constant over time, meaning its rate of formation equals its rate of breakdown.\n$$\\text{Rate of formation of } ES = k_1 [E][S]$$\n$$\\text{Rate of breakdown of } ES = k_{-1}[ES] + k_{\\mathrm{cat}}[ES] = (k_{-1} + k_{\\mathrm{cat}})[ES]$$\nAt steady state:\n$$k_1 [E][S] = (k_{-1} + k_{\\mathrm{cat}})[ES]$$\nNow, we substitute the expression for $[E]$ into the steady-state equation:\n$$k_1 \\left( \\frac{[E]_{\\mathrm{T}} - [ES]}{1 + \\frac{[I]}{K_i}} \\right) [S] = (k_{-1} + k_{\\mathrm{cat}})[ES]$$\nWe rearrange this equation to solve for $[ES]$.\n$$k_1 ([E]_{\\mathrm{T}} - [ES]) [S] = (k_{-1} + k_{\\mathrm{cat}}) \\left(1 + \\frac{[I]}{K_i}\\right) [ES]$$\n$$k_1 [E]_{\\mathrm{T}} [S] - k_1 [ES] [S] = (k_{-1} + k_{\\mathrm{cat}}) \\left(1 + \\frac{[I]}{K_i}\\right) [ES]$$\n$$k_1 [E]_{\\mathrm{T}} [S] = \\left[ k_1 [S] + (k_{-1} + k_{\\mathrm{cat}}) \\left(1 + \\frac{[I]}{K_i}\\right) \\right] [ES]$$\nNext, we divide both sides by the term in brackets to isolate $[ES]$:\n$$[ES] = \\frac{k_1 [E]_{\\mathrm{T}} [S]}{k_1 [S] + (k_{-1} + k_{\\mathrm{cat}}) \\left(1 + \\frac{[I]}{K_i}\\right)}$$\nThe velocity in the presence of the inhibitor, $v_i$, is $k_{\\mathrm{cat}}[ES]$.\n$$v_i = \\frac{k_{\\mathrm{cat}} k_1 [E]_{\\mathrm{T}} [S]}{k_1 [S] + (k_{-1} + k_{\\mathrm{cat}}) \\left(1 + \\frac{[I]}{K_i}\\right)}$$\nTo simplify, we divide the numerator and denominator by $k_1$:\n$$v_i = \\frac{k_{\\mathrm{cat}} [E]_{\\mathrm{T}} [S]}{[S] + \\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1} \\left(1 + \\frac{[I]}{K_i}\\right)}$$\nWe define the Michaelis constant as $K_m = \\frac{k_{-1} + k_{\\mathrm{cat}}}{k_1}$ and the maximum velocity as $V_{\\max} = k_{\\mathrm{cat}} [E]_{\\mathrm{T}}$. Substituting these definitions yields the Michaelis-Menten equation for competitive inhibition:\n$$v_i = \\frac{V_{\\max} [S]}{[S] + K_m \\left(1 + \\frac{[I]}{K_i}\\right)}$$\nThis equation has the same form as the standard Michaelis-Menten equation, but with an apparent Michaelis constant, $K_{m,app}$, where\n$$K_{m,app} = K_m \\left(1 + \\frac{[I]}{K_i}\\right)$$\nThis successfully derives the apparent Michaelis constant as requested.\n\nNow, we compute the ratio of the initial velocity in the presence of the inhibitor, $v_i$, to the initial velocity in its absence, $v_0$. The velocity in the absence of inhibitor ($[I]=0$) is given by the standard Michaelis-Menten equation:\n$$v_0 = \\frac{V_{\\max} [S]}{[S] + K_m}$$\nThe ratio $\\frac{v_i}{v_0}$ is:\n$$\\frac{v_i}{v_0} = \\frac{\\frac{V_{\\max} [S]}{[S] + K_m \\left(1 + \\frac{[I]}{K_i}\\right)}}{\\frac{V_{\\max} [S]}{[S] + K_m}}$$\nThe terms $V_{\\max}$ and $[S]$ cancel out, leaving:\n$$\\frac{v_i}{v_0} = \\frac{[S] + K_m}{[S] + K_m \\left(1 + \\frac{[I]}{K_i}\\right)}$$\nWe now substitute the given experimental parameters: $K_m = 3.0\\,\\mu\\mathrm{M}$, $[S] = 1.50\\,\\mu\\mathrm{M}$, $[I] = 0.90\\,\\mu\\mathrm{M}$, and $K_i = 0.60\\,\\mu\\mathrm{M}$. The concentration units ($\\mu\\mathrm{M}$) are consistent and will cancel in the ratio.\n$$\\frac{v_i}{v_0} = \\frac{1.50 + 3.0}{1.50 + 3.0 \\left(1 + \\frac{0.90}{0.60}\\right)}$$\nFirst, calculate the term inside the parenthesis:\n$$1 + \\frac{0.90}{0.60} = 1 + 1.5 = 2.5$$\nNow substitute this back into the main expression:\n$$\\frac{v_i}{v_0} = \\frac{1.50 + 3.0}{1.50 + 3.0(2.5)} = \\frac{4.50}{1.50 + 7.5} = \\frac{4.50}{9.00}$$\n$$\\frac{v_i}{v_0} = 0.5$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$0.5000$$",
            "answer": "$$\\boxed{0.5000}$$"
        },
        {
            "introduction": "Shifting our focus from DPP-4 inhibitors to the other major class of incretin-based therapies, GLP-1 receptor agonists (GLP-1 RAs) are designed to have a much longer duration of action than endogenous GLP-1. This practice delves into the pharmacokinetics that make this possible, asking you to derive the fundamental equation for drug half-life ($t_{1/2}$) from clearance ($CL$) and volume of distribution ($V$). By applying this to a modern GLP-1 RA, you will quantify its persistence in the body and understand why its structure makes it resistant to the DPP-4 enzyme .",
            "id": "4958146",
            "problem": "A glucagon-like peptide-1 receptor agonist (GLP-1RA) administered systemically is modeled by a one-compartment disposition with first-order elimination. Starting from the definition of clearance and volume of distribution, derive the expression for the effective terminal half-life in terms of the volume of distribution $V$ and the clearance $CL$, under the assumption of first-order elimination. Then, using the derived expression, calculate the half-life for semaglutide given the following typical adult pharmacokinetic parameters: $V = 12.5$ L and $CL = 0.050$ L/h. Express your final answer in hours and round to three significant figures. Also briefly justify why dipeptidyl peptidase-4 (DPP-4) inhibition changes the half-life of endogenous glucagon-like peptide-1 (GLP-1) in this framework but is not expected to change the half-life of a DPP-4–resistant GLP-1RA like semaglutide.",
            "solution": "The fundamental base is first-order elimination kinetics in a one-compartment model, together with core pharmacokinetic definitions. Let $C(t)$ denote the plasma concentration of the drug at time $t$. Under first-order elimination, the rate of change of concentration is proportional to the concentration:\n$$\n\\frac{dC(t)}{dt} = -k\\,C(t),\n$$\nwhere $k$ is the first-order elimination rate constant. The solution of this differential equation with initial condition $C(0)=C_{0}$ is\n$$\nC(t) = C_{0}\\,\\exp(-k\\,t).\n$$\nThe effective terminal half-life $t_{1/2}$ is defined as the time required for the concentration to decrease to one-half of its initial value:\n$$\nC(t_{1/2}) = \\frac{1}{2}C_{0}.\n$$\nSubstituting the exponential solution and solving for $t_{1/2}$,\n$$\nC_{0}\\,\\exp(-k\\,t_{1/2}) = \\frac{1}{2}C_{0}\n\\quad\\Rightarrow\\quad\n\\exp(-k\\,t_{1/2}) = \\frac{1}{2}\n\\quad\\Rightarrow\\quad\n-k\\,t_{1/2} = \\ln\\!\\left(\\frac{1}{2}\\right) = -\\ln 2\n\\quad\\Rightarrow\\quad\nt_{1/2} = \\frac{\\ln 2}{k}.\n$$\nTo connect $k$ to the core pharmacokinetic parameters, we use the definition of clearance in a one-compartment model. Clearance $CL$ is the proportionality constant that relates the rate of elimination to the concentration, and the elimination rate constant satisfies\n$$\nk = \\frac{CL}{V},\n$$\nwhere $V$ is the volume of distribution. Substituting this relation into the expression for $t_{1/2}$ gives\n$$\nt_{1/2} = \\frac{\\ln 2}{k} = \\frac{\\ln 2}{CL/V} = \\frac{\\ln 2 \\cdot V}{CL}.\n$$\nNow compute $t_{1/2}$ for semaglutide using $V = 12.5$ L and $CL = 0.050$ L/h:\n$$\nt_{1/2} = \\frac{\\ln 2 \\cdot 12.5}{0.050}.\n$$\nUsing $\\ln 2 \\approx 0.693147\\,$,\n$$\nt_{1/2} \\approx \\frac{0.693147 \\times 12.5}{0.050} = \\frac{8.6643375}{0.050} = 173.28675\\ \\text{hours}.\n$$\nRounded to three significant figures and expressed in hours, this is $173$ hours.\n\nFinally, regarding dipeptidyl peptidase-4 (DPP-4) inhibition: DPP-4 inhibition reduces enzymatic degradation of endogenous glucagon-like peptide-1 (GLP-1), effectively decreasing the metabolic component of $CL$ for endogenous GLP-1, which increases $t_{1/2}$ via $t_{1/2} = \\frac{\\ln 2 \\cdot V}{CL}$. In contrast, semaglutide is engineered to be resistant to DPP-4 cleavage; therefore, DPP-4 inhibition does not materially reduce its $CL$, and its $t_{1/2}$ remains governed by non–DPP-4 pathways and the parameters $V$ and $CL$ shown above.",
            "answer": "$$\\boxed{173}$$"
        }
    ]
}